Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
225Ac-DOTA-Daratumumab in Relapsed/Refractory Multiple Myeloma
NCT05363111Phase 1Recruiting
- Sponsor
- City of Hope
- Start
- Nov 2022
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 225Ac-DOTA-daratumumab in multiple myeloma (MM), sponsored by City of Hope. Primary endpoints: Incidence of dose-limiting toxicities at 6 weeks and Maximum tolerated dose at 6 weeks. Started Nov 2022; status: recruiting.
02
Drugs
225Ac-DOTA-daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05363111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363111.